BioPharma Resources

Drug Trial Radar · NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,123 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,123

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

May 24, 2032

Study completion May 24, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

Conditions

  • Endometrial Cancer

Interventions

  • PembrolizumabBiological

    Intravenous (IV) Infusion

  • CarboplatinDrug

    During the Induction Phase, participants receive carboplatin AUC 5 (mg/mL/min) on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • PaclitaxelDrug

    During the Induction Phase, participants receive paclitaxel 175 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • DocetaxelDrug

    During the Induction Phase, participants may receive docetaxel (in place of paclitaxel) 75 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion.

  • Sacituzumab TirumotecanBiological

    IV Infusion

  • CisplatinDrug

    During the Induction Phase, participants may receive cisplatin (in place of carboplatin) 75 mg/m\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months) via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintenance Treatment: Progression-Free Survival (PFS)Time frame: Up to approximately 44 months
  2. Maintenance Treatment: Overall Survival (OS)Time frame: Up to approximately 54 months

Locations

272 sites in 34 countries. Site status is shown where the registry gives one.

  • University of South Alabama, Mitchell Cancer Institute ( Site 6033)

    Mobile, Alabama · Recruiting

  • Alaska Women's Cancer Care ( Site 6036)

    Anchorage, Alaska · Recruiting

  • CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014)

    Irvine, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)

    Orange, California · Recruiting

  • Sansum Clinic (Ridley Tree) ( Site 8007)

    Solvang, California · Recruiting

  • John Muir Health Cancer Center ( Site 6028)

    Walnut Creek, California · Recruiting

  • Yale University School of Medicine ( Site 6009)

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center ( Site 5005)

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialists - South ( Site 7003)

    Fort Myers, Florida · Recruiting

  • UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026)

    Gainesville, Florida · Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 6031)

    Miami Beach, Florida · Recruiting

  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists ( Site 7002)

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists East ( Site 7001)

    West Palm Beach, Florida · Recruiting

  • St. Joseph's/Candler Health System ( Site 6021)

    Savannah, Georgia · Recruiting

  • University of Chicago Medical Center ( Site 5002)

    Chicago, Illinois · Recruiting

  • Parkview Research Center ( Site 6008)

    Fort Wayne, Indiana · Recruiting

  • Women's Cancer Care ( Site 6010)

    Covington, Louisiana · Recruiting

  • TRIALS 365 ( Site 6005)

    Shreveport, Louisiana · Recruiting

  • Maine Medical Center - Scarborough Campus ( Site 6042)

    Scarborough, Maine · Recruiting

  • Tufts Medical Center ( Site 6052)

    Boston, Massachusetts · Recruiting

  • Minnesota Oncology Hematology, PA ( Site 8003)

    Minneapolis, Minnesota · Recruiting

  • St. Dominic's Hospital ( Site 5004)

    Jackson, Mississippi · Recruiting

  • Washington University - School of Medicine ( Site 5006)

    St Louis, Missouri · Recruiting

  • The Center of Hope ( Site 5018)

    Reno, Nevada · Recruiting

  • Holy Name Medical Center ( Site 6011)

    Teaneck, New Jersey · Recruiting

  • University of New Mexico Comprehensive Cancer Center ( Site 6046)

    Albuquerque, New Mexico · Recruiting

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 6055)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6004)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 6053)

    New York, New York · Recruiting

  • Duke Cancer Institute ( Site 6049)

    Durham, North Carolina · Recruiting

  • FirstHealth of the Carolinas ( Site 6037)

    Pinehurst, North Carolina · Recruiting

  • Miami Valley Hospital South ( Site 6014)

    Centerville, Ohio · Recruiting

  • University of Cincinnati Medical Center ( Site 5013)

    Cincinnati, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)

    Columbus, Ohio · Recruiting

  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 5001)

    Kettering, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center ( Site 6012)

    Oklahoma City, Oklahoma · Recruiting

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6047)

    Tulsa, Oklahoma · Recruiting

  • Oncology Associates of Oregon, P.C. ( Site 8005)

    Eugene, Oregon · Recruiting

  • St. Luke's University Health Network ( Site 6041)

    Bethlehem, Pennsylvania · Recruiting

Showing 40 of 272 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.